Multiple Sclerosis Journal - October 2017 - 1478

Multiple Sclerosis Journal 23(11)
multiple sclerosis using PET imaging and the
radioligand 11C-PK11195. J Nucl Med 2014; 55:
939-944.
11. Guo Q, Owen DR, Rabiner EA, et al. Identifying
improved TSPO PET imaging probes through
biomathematics: The impact of multiple TSPO
binding sites in vivo. Neuroimage 2012; 60: 902-910.
12. Cosenza-Nashat M, Zhao ML, Suh HS, et al.
Expression of the translocator protein of 18 kDa
by microglia, macrophages and astrocytes based
on immunohistochemical localization in abnormal
human brain. Neuropathol Appl Neurobiol 2009; 35:
306-328.
13. Polman CH, Reingold SC, Banwell B, et al.
Diagnostic criteria for multiple sclerosis: 2010
revisions to the McDonald criteria. Ann Neurol 2011;
69: 292-302.
14. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa
translocator protein (TSPO) polymorphism explains
differences in binding affinity of the PET radioligand
PBR28. J Cereb Blood Flow Metab 2012; 32: 1-5.
15. Bagory M, Durand-Dubief F, Ibarrola D, et al.
Implementation of an absolute brain 1H-MRS
quantification method to assess different tissue
alterations in multiple sclerosis. IEEE Trans Biomed
Eng 2012; 59: 2687-2694.

SAGE journals
1478

24. Garvey LJ, Pavese N, Ramlackhansingh A, et al.
Acute HCV/HIV coinfection is associated with
cognitive dysfunction and cerebral metabolite
disturbance, but not increased microglial cell
activation. PLoS ONE 2012; 7: e38980.
25. Popescu BF, Pirko I and Lucchinetti CF. Pathology
of multiple sclerosis: Where do we stand? Continuum
2013; 19: 901-921.
26. Brex PA, Parker GJ, Leary SM, et al. Lesion
heterogeneity in multiple sclerosis: A study of the
relations between appearances on T1 weighted images,
T1 relaxation times, and metabolite concentrations. J
Neurol Neurosurg Psychiatry 2000; 68: 627-632.
27. Murray ME, Przybelski SA, Lesnick TG, et al.
Early Alzheimer's disease neuropathology detected
by proton MR spectroscopy. J Neurosci 2014; 34:
16247-16255.
28. Magliozzi R, Howell OW, Reeves C, et al. A gradient
of neuronal loss and meningeal inflammation in
multiple sclerosis. Ann Neurol 2010; 68: 477-493.

16. Ogg RJ, Kingsley PB, Taylor JS, et al. WET, a T1and B1-insensitive water-suppression method for in
vivo localized 1H NMR spectroscopy. J Magn Reson
B 1994; 104: 1-10.

29. Vercellino M, Masera S, Lorenzatti M, et al.
Demyelination, inflammation, and neurodegeneration
in multiple sclerosis deep gray matter. J Neuropathol
Exp Neurol 2009; 68: 489-502.

17. Provencher SW. Estimation of metabolite
concentrations from localized in vivo proton NMR
spectra. Magn Reson Med 1993; 30: 672-679.

30. Llufriu S, Kornak J, Ratiney H, et al. Magnetic
resonance spectroscopy markers of disease
progression in multiple sclerosis. JAMA Neurol 2014;
71: 840-847.

18. Sarchielli P, Presciutti O, Pelliccioli GP, et al.
Absolute quantification of brain metabolites by
proton magnetic resonance spectroscopy in normalappearing white matter of multiple sclerosis patients.
Brain 1999; 122(Pt 3): 513-521.

Visit SAGE journals online
journals.sagepub.com/
home/msj

23. Guo Q, Owen DR, Rabiner EA, et al. A graphical
method to compare the in vivo binding potential of
PET radioligands in the absence of a reference region:
Application to [11C]PBR28 and [18F]PBR111 for
TSPO imaging. J Cereb Blood Flow Metab 2014; 34:
1162-1168.

31. De Stefano N, Filippi M, Miller D, et al. Guidelines
for using proton MR spectroscopy in multicenter
clinical MS studies. Neurology 2007; 69: 1942-1952.

19. Smith SM, Zhang Y, Jenkinson M, et al. Accurate,
robust, and automated longitudinal and crosssectional brain change analysis. Neuroimage 2002;
17: 479-489.

32. Audoin B, Ibarrola D, Malikova I, et al. Onset
and underpinnings of white matter atrophy at the
very early stage of multiple sclerosis - A two-year
longitudinal MRI/MRSI study of corpus callosum.
Mult Scler 2007; 13: 41-51.

20. Logan J, Fowler JS, Volkow ND, et al. Distribution
volume ratios without blood sampling from graphical
analysis of PET data. J Cereb Blood Flow Metab
1996; 16: 834-840.

33. Giannetti P, Politis M, Su P, et al. Increased
PK11195-PET binding in normal-appearing white
matter in clinically isolated syndrome. Brain 2015;
138: 110-119.

21. Collste K, Forsberg A, Varrone A, et al. Test-retest
reproducibility of [(11)C]PBR28 binding to TSPO
in healthy control subjects. Eur J Nucl Med Mol
Imaging 2016; 43: 173-183.

34. Politis M, Giannetti P, Su P, et al. Increased
PK11195 PET binding in the cortex of patients with
MS correlates with disability. Neurology 2012; 79:
523-530.

22. Salinas CA, Searle GE and Gunn RN. The simplified
reference tissue model: Model assumption violations
and their impact on binding potential. J Cereb Blood
Flow Metab 2015; 35: 304-311.

35. Parker CA, Nabulsi N, Holden D, et al. Evaluation
of 11C-BU99008, a PET ligand for the imidazoline2
binding sites in rhesus brain. J Nucl Med 2014; 55:
838-844.
journals.sagepub.com/home/msj
http://journals.sagepub.com/ https://journals.sagepub.com/home/msj
Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017
